Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab, Lenvatinib, N-803, and AdHER2DC Vaccine in HER2+ Endometrial Cancer
NCT06253494Phase 2Recruiting
- Sponsor
- National Cancer Institute
- Start
- May 2024
- Primary completion
- Dec 2026
- Modality
- Whole Cell Cancer Vaccines, Cytokines & Interferons, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of her2 pulsed dendritic cell vaccine, nogapendekin alfa inbakicept in endometrial cancer (EC), sponsored by National Cancer Institute. Started May 2024; status: recruiting.
02
Drugs
her2 pulsed dendritic cell vaccinenogapendekin alfa inbakicept
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on NCT06253494.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06253494.